Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients

: Beyond lowering plasma glucose levels, sodium–glucose cotransporter 2 inhibitors (SGLT2is) significantly reduce hospitalization for heart failure (HF) and retard the progression of chronic kidney disease (CKD) in patients with type 2 diabetes. Endothelial dysfunction is not only involved in the development and progression of cardiovascular disease (CVD), but is also associated with the progression of CKD. In patients with type 2 diabetes, hyperglycemia, insulin resistance, hyperinsulinemia and dyslipidemia induce the development of endothelial dysfunction. SGLT2is have been shown to improve endothelial dysfunction, as assessed by flow-mediated vasodilation, in individuals at high risk of CVD. Along with an improvement in endothelial dysfunction, SGLT2is have been shown to improve oxidative stress, inflammation, mitochondrial dysfunction, glucotoxicity, such as the advanced signaling of glycation end products, and nitric oxide bioavailability. The improvements in endothelial dysfunction and such endothelium-derived factors may play an important role in preventing the development of coronary artery disease, coronary microvascular dysfunction and diabetic cardiomyopathy, which cause HF, and play a role in retarding CKD. The suppression of the development of HF and the progression of CKD achieved by SGLT2is might have been largely induced by their capacity to improve vascular endothelial function.

[1]  V. Fuster,et al.  Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction , 2023, Circulation. Cardiovascular imaging.

[2]  P. Puchalska,et al.  Ketones and the Heart: Metabolic Principles and Therapeutic Implications , 2023, Circulation research.

[3]  H. Hashiguchi,et al.  Luseogliflozin and caloric intake restriction increase superoxide dismutase 2 expression, promote antioxidative effects, and attenuate aortic endothelial dysfunction in diet‐induced obese mice , 2023, Journal of diabetes investigation.

[4]  J. Balschi,et al.  SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  M. Nangaku,et al.  Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study , 2023, Journal of diabetes investigation.

[6]  F. Bonnet,et al.  Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance? , 2023, Diabetes & metabolism.

[7]  R. de Caterina,et al.  Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signaling pathway in diabetic cardiomyopathy. , 2023, Cardiovascular research.

[8]  F. Fujiyama,et al.  Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca2+ handling in ventricular cardiomyocytes. , 2023, American journal of physiology. Heart and circulatory physiology.

[9]  L. Niskanen,et al.  Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. , 2023, Diabetes & metabolism.

[10]  Ziyu Guo,et al.  Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice , 2022, Frontiers in Cardiovascular Medicine.

[11]  A. Lymperopoulos,et al.  Autonomic Nervous System Regulation of Epicardial Adipose Tissue: Potential Roles for Regulator of G Protein Signaling-4 , 2022, Current issues in molecular biology.

[12]  Lie Xiong,et al.  Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy , 2022, Frontiers in Endocrinology.

[13]  Jinhua Zhang,et al.  Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy , 2022, Frontiers in Cardiovascular Medicine.

[14]  A. De Angelis,et al.  Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary , 2022, Frontiers in Cardiovascular Medicine.

[15]  M. Mayr,et al.  SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism. , 2022, Circulation.

[16]  Christian Catalini,et al.  Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options , 2022, Biomedicines.

[17]  Akshay S. Desai,et al.  Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER , 2022, Nature Medicine.

[18]  R. Leask,et al.  Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption , 2022, Scientific Reports.

[19]  G. Santulli,et al.  SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients , 2022, Hypertension.

[20]  C. Papadopoulos,et al.  META-ANALYSIS ADDRESSING THE EFFECT OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS ON FLOW-MEDIATED DILATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. , 2022, Journal of hypertension.

[21]  Xinyuan Huang,et al.  Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function , 2022, Oxidative medicine and cellular longevity.

[22]  Sheng Li,et al.  Endothelial Dysfunction and Diabetic Cardiomyopathy , 2022, Frontiers in Endocrinology.

[23]  F. Gao,et al.  Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis , 2022, Frontiers in Cardiovascular Medicine.

[24]  Jin Liu,et al.  Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis , 2022, Frontiers in Endocrinology.

[25]  A. Lymperopoulos,et al.  Short-Chain Fatty Acid Receptors and Cardiovascular Function , 2022, International journal of molecular sciences.

[26]  J. Badimón,et al.  Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial. , 2022, Diabetes & metabolic syndrome.

[27]  Dong Zhou,et al.  Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis , 2021, Frontiers in Medicine.

[28]  N. Brunetti,et al.  Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure , 2021, Cardiovascular Drugs and Therapy.

[29]  J. McMurray,et al.  A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. , 2021, Kidney international.

[30]  Dong Li,et al.  Sodium-glucose cotransporter 2 inhibitors Benefit to Kidney and Cardiovascular Outcomes for Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease 3b-4: A Systematic Review And Meta-analysis of Randomized Clinical Trials. , 2021, Diabetes research and clinical practice.

[31]  M. Michal,et al.  Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population , 2021, Journal of clinical medicine.

[32]  V. Fuster,et al.  Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study. , 2021, JACC. Heart failure.

[33]  L. Tian,et al.  Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials , 2021, Frontiers in Pharmacology.

[34]  Mei Qiu,et al.  Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs , 2021, American Journal of Cardiovascular Drugs.

[35]  A. Lymperopoulos,et al.  Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin’s Effects in the Adrenal Gland , 2021, International journal of molecular sciences.

[36]  Xin Du,et al.  The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials , 2021, Frontiers in Clinical Diabetes and Healthcare.

[37]  Jinyu Pan,et al.  Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats , 2021, Journal of cellular and molecular medicine.

[38]  H. Katsuyama,et al.  Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors , 2021, International journal of molecular sciences.

[39]  Daoquan Peng,et al.  Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials , 2021, Journal of cardiovascular pharmacology.

[40]  Q. Su,et al.  Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis , 2021, Cardiology research and practice.

[41]  Yi‐Jen Chen,et al.  Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats , 2021, International journal of molecular sciences.

[42]  V. Fuster,et al.  Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction. , 2020, Journal of the American College of Cardiology.

[43]  V. Fuster,et al.  Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. , 2020, JACC. Cardiovascular imaging.

[44]  J. Mehta,et al.  Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. , 2020, American heart journal.

[45]  Jin-Yu Sun,et al.  Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis , 2020, American Journal of Cardiovascular Drugs.

[46]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[47]  K. Node,et al.  Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study , 2020, Endocrinology, diabetes & metabolism.

[48]  Tomohiro Fujisaki,et al.  Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis , 2020, Cardiovascular Diabetology.

[49]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[50]  N. Hashimoto,et al.  Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease , 2020, Journal of atherosclerosis and thrombosis.

[51]  S. Verma,et al.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors , 2020, JACC. Basic to translational science.

[52]  P. Boor,et al.  Empagliflozin improves left ventricular diastolic function of db/db mice. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[53]  M. Nezu,et al.  Roles of Nrf2 in Protecting the Kidney from Oxidative Damage , 2020, International journal of molecular sciences.

[54]  D. Freimark,et al.  Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy , 2020, Cardiovascular Diabetology.

[55]  H. Yanai Dipeptidyl Peptidase-4 Inhibitor Versus Sodium-Glucose Cotransporter-2 Inhibitor in the Management of Type 2 Diabetes , 2019 .

[56]  W. Paulus,et al.  Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin , 2019, JACC. Basic to translational science.

[57]  Liming Chen,et al.  Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. , 2019, Clinical science.

[58]  K. Hosoda,et al.  Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study , 2019, Journal of diabetes investigation.

[59]  A. Sezai,et al.  Canagliflozin for Japanese patients with chronic heart failure and type II diabetes , 2019, Cardiovascular Diabetology.

[60]  S. Miura,et al.  Effects of Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial and Diastolic Function in Heart Failure With Preserved Ejection Fraction ― Novel Prospective Cohort Study ― , 2019, Circulation reports.

[61]  N. Ward,et al.  SGLT2 Inhibitor–Induced Sympathoinhibition , 2019, JACC. Basic to translational science.

[62]  M. Jardine,et al.  Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis , 2019, Diabetes, obesity & metabolism.

[63]  V. Fuster,et al.  Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. , 2019, Journal of the American College of Cardiology.

[64]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[65]  A. Ramirez,et al.  Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril , 2019, Journal of hypertension.

[66]  S. Göpel,et al.  SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice , 2019, Cardiovascular Diabetology.

[67]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[68]  C. Wanner,et al.  Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial , 2019, Journal of diabetes investigation.

[69]  D. Tousoulis,et al.  Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis , 2018, Journal of diabetes research.

[70]  E. Pow,et al.  Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects , 2018, Stem cells international.

[71]  K. Kario,et al.  Endothelial Dysfunction, Increased Arterial Stiffness, and Cardiovascular Risk Prediction in Patients With Coronary Artery Disease: FMD‐J (Flow‐Mediated Dilation Japan) Study A , 2018, Journal of the American Heart Association.

[72]  E. Pfarr,et al.  Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons , 2018, Diabetes Therapy.

[73]  J. McMurray,et al.  Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction , 2018, Diabetes Care.

[74]  J. Sowers,et al.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.

[75]  J. Shaw,et al.  Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[76]  R. Guthrie Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[77]  Si-Si Dong,et al.  Phlorizin Exerts Direct Protective Effects on Palmitic Acid (PA)-Induced Endothelial Dysfunction by Activating the PI3K/AKT/eNOS Signaling Pathway and Increasing the Levels of Nitric Oxide (NO) , 2018, Medical science monitor basic research.

[78]  Jianwei Cao,et al.  Dimethylarginine Dimethylaminohydrolase 1 Deficiency Induces the Epithelial to Mesenchymal Transition in Renal Proximal Tubular Epithelial Cells and Exacerbates Kidney Damage in Aged and Diabetic Mice. , 2017, Antioxidants & redox signaling.

[79]  H. Yanai,et al.  The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4 , 2017, Journal of clinical medicine research.

[80]  L. Ghiadoni,et al.  Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study , 2017, Cardiovascular Diabetology.

[81]  H. Yanai Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes. , 2017, Annals of translational medicine.

[82]  B. Zinman,et al.  Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[83]  H. Uchino,et al.  Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study , 2017, Cardiovascular Diabetology.

[84]  Yang Li,et al.  Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis , 2017, PeerJ.

[85]  Wei Wu,et al.  The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway , 2017, Cellular Physiology and Biochemistry.

[86]  H. Yanai,et al.  A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production , 2016, Journal of clinical medicine research.

[87]  M. Sata,et al.  Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse , 2016, Front. Cardiovasc. Med..

[88]  Y. Shiraishi,et al.  Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys , 2016, Journal of clinical medicine research.

[89]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[90]  A. Avogaro,et al.  Levels of Circulating Progenitor Cells, Cardiovascular Outcomes and Death: A Meta-Analysis of Prospective Observational Studies. , 2016, Circulation research.

[91]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[92]  C. Cannon,et al.  Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[93]  V. Aboyans,et al.  The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. , 2015, Atherosclerosis.

[94]  T. Münzel,et al.  The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity , 2014, PloS one.

[95]  K. Poh,et al.  Endothelial progenitor cells in cardiovascular diseases. , 2014, World journal of stem cells.

[96]  S. Dikalov,et al.  Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. , 2013, Antioxidants & redox signaling.

[97]  G. Wolf,et al.  Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse. , 2013, American journal of physiology. Renal physiology.

[98]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[99]  J. Madden Role of the vascular endothelium and plaque in acute ischemic stroke , 2012, Neurology.

[100]  F. Rutten,et al.  High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes , 2012, Diabetologia.

[101]  M. Davids,et al.  Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. , 2012, American journal of physiology. Heart and circulatory physiology.

[102]  N. Toda,et al.  How mental stress affects endothelial function , 2011, Pflügers Archiv - European Journal of Physiology.

[103]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[104]  R. Sotníková,et al.  Nitric oxide--the endothelium-derived relaxing factor and its role in endothelial functions. , 2010, General physiology and biophysics.

[105]  G. Wolf,et al.  Erythropoietin Protects Podocytes from Damage by Advanced Glycation End-Products , 2010, Nephron Experimental Nephrology.

[106]  D. Fliser Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. , 2010, Journal of nephrology.

[107]  H. Toba,et al.  Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. , 2009, European journal of pharmacology.

[108]  S. Yamagishi,et al.  Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD). , 2009, Life sciences.

[109]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[110]  H. Parving,et al.  Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study , 2008, Scandinavian journal of clinical and laboratory investigation.

[111]  T. Naruko,et al.  [Risk factors for heart failure]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[112]  Amit Sharma,et al.  Isoliquiritigenin inhibits IκB kinase activity and ROS generation to block TNF-α induced expression of cell adhesion molecules on human endothelial cells , 2007 .

[113]  V. Vallon,et al.  Adenosine and kidney function. , 2006, Physiological reviews.

[114]  C. Baylis Arginine, arginine analogs and nitric oxide production in chronic kidney disease , 2006, Nature Clinical Practice Nephrology.

[115]  Zhihong Yang,et al.  Recent advances in understanding endothelial dysfunction in atherosclerosis. , 2006, Clinical medicine & research.

[116]  R. Medcalf,et al.  Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. , 2005, Biochemical and biophysical research communications.

[117]  J. Cooke,et al.  Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA , 2005, Vascular medicine.

[118]  L. Ghiadoni,et al.  Endothelial dysfunction and oxidative stress in chronic renal failure. , 2004, Journal of nephrology.

[119]  O. McGuinness,et al.  Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. , 2004, Diabetes.

[120]  D. Tsikas,et al.  Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans , 2004, Circulation.

[121]  T. Münzel,et al.  ADMA and oxidative stress. , 2003, Atherosclerosis. Supplements.

[122]  M. Andrassy,et al.  Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.

[123]  K. Borch-Johnsen,et al.  Elevated Urinary Albumin Excretion Is Associated With Impaired Arterial Dilatory Capacity in Clinically Healthy Subjects , 2001, Circulation.

[124]  S. Jacob,et al.  Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. , 2000, Circulation.

[125]  M. Quon,et al.  Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. , 2000, Circulation.

[126]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[127]  R. Blantz,et al.  Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. , 1999, Journal of the American Society of Nephrology : JASN.

[128]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[129]  K. Nakao,et al.  T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. , 1999, Circulation.

[130]  B. Sobel,et al.  Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. , 1998, Circulation.

[131]  G. Remuzzi,et al.  Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. , 1998, The Journal of clinical investigation.

[132]  P. Vallance,et al.  Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. , 1997, Kidney international.

[133]  M. Quon,et al.  Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. , 1996, The Journal of clinical investigation.

[134]  K. Nakao,et al.  Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. , 1996, Circulation.

[135]  Hirofumiyasue,et al.  Nitric Oxide Activity Is Deficient in Spasm Arteries of Patients With Coronary Spastic Angina , 1996 .

[136]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[137]  Raphaela P. Kerindongo,et al.  Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells. , 2019, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.

[138]  A. Dear,et al.  Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis , 2018, Diabetes & vascular disease research.

[139]  V. Vallon,et al.  Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. , 2012, American journal of physiology. Regulatory, integrative and comparative physiology.

[140]  K. Node,et al.  Renovascular protective effects of erythropoietin in patients with chronic kidney disease. , 2011, Internal medicine.

[141]  C. Zoccali,et al.  The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[142]  D. Bell,et al.  Diabetic cardiomyopathy. , 2003, Diabetes care.

[143]  E. Stankevičius,et al.  [Role of nitric oxide and other endothelium-derived factors]. , 2003, Medicina.

[144]  D. Fliser,et al.  Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. , 2002, Journal of the American Society of Nephrology : JASN.